Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Expert Review of Anticancer Therapy|April 20, 2024
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-childJennifer C Keenan, Arielle J Medford, Charles S Dai, et al.
The Oncologist|August 2, 2022
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to AbemaciclibSeth A Wander, Neil O'Brien, Lacey M Litchfield, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 20, 2025
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast CancerJimmitti Teysir, Maxwell R Lloyd, Samer Alkassis, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 25, 2025
Diffuse peritoneal inclusion cysts masquerading as disseminated gynecologic malignancy in post-menopausal females: Two cases and a review of the literatureHadley W Reid, Seth A Wander, Carlos Parra-Herran, et al.
Breast Cancer Research : BCR|August 14, 2025
Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancerLis Victoria Ravani, Zahra Bagheri, Adam M Brufsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2009
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motilityMichelle D Larrea, Feng Hong, Seth A Wander, et al.
Breast Cancer Research and Treatment|July 30, 2010
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivoYi Chen, Edwin A Alvarez, Diana Azzam, et al.
JCO Oncology Practice|December 17, 2024
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast CancerLis Victoria Ravani, Pedro Calomeni, Maysa Vilbert, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2019
p27 transcriptionally coregulates cJun to drive programs of tumor progressionHyunho Yoon, Minsoon Kim, Kibeom Jang, et al.
Therapeutic Advances in Medical Oncology|December 22, 2025
Current landscape of sequencing ADCs in metastatic breast cancerShannon McLaughlin, Lis V Ravani, Beverly Moy, et al.
Pageof 8